The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued products.

GlobalData tracks 15 drugs in development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections by 13 companies/universities/institutes. The top development phase for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections is preclinical with 11 drugs in that stage. The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline has nine drugs in development by companies and six by universities/ institutes. Some of the companies in the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline products market are: University of Notre Dame, Wockhardt and Helmholtz Centre for Infection Research.

The key targets in the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline products market include Lipid II, Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10), and Oxacillinase (OXA or EC 3.5.2.6).

The key mechanisms of action in the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline product include Peptidoglycan (Murein) Inhibitor with one drug in Preclinical. The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline products include seven routes of administration with the top ROA being Oral and three key molecule types in the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline products market including Small Molecule, and Synthetic Peptide.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections overview

Vancomycin-resistant Staphylococcus aureus (VRSA) infection occurs when Staphylococcus aureus becomes resistant to the antibiotic vancomycin. Risk factors include taking strong antibiotics the wrong way, which may cause the bacteria to develop resistance to the antibiotics; a weak immune system, and long hospital stays. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

For a complete picture of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.